Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$60.1MBeat by $4.3M
EPS-$0.83Beat by $0.03
Revenue estimate$55.8M
EPS estimate-$0.86

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$84.5M
EPS estimate-$0.72

Financials

Q1 2026

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.94B+77.3%
Enterprise value$5.99B+78.4%
P/S27.3×+2.9×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Segments

By segment

See full
Single reportable segment$60.1M+83.8%

By product

See full
License revenue-+100%

FAQ

When did Rhythm Pharmaceuticals, Inc. report Q1 2026 earnings?
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Rhythm Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Rhythm Pharmaceuticals, Inc. reported revenue of $60.1M and eps of $-0.83 for Q1 2026.
Did Rhythm Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $55.8M by $4.3M. EPS beat the consensus estimate of $-0.86 by $0.03.
How did Rhythm Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 83.8% from $32.7M a year earlier and eps declined 2.5% from $-0.81.
Where can I find Rhythm Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-030136) and the 10-Q periodic report (0001628280-26-030549) directly on SEC EDGAR. The filing index links above go to sec.gov.